Quick Answer
RELMADA THERAPEUTICS, INC. reported Operating Income of -$59.10 million for fiscal year 2025.
RELMADA THERAPEUTICS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$59.10M | +29.6% |
| 2024 | -$83.89M | +19.1% |
| 2023 | -$103.70M | +35.7% |
| 2022 | -$161.25M | -28.3% |
| 2021 | -$125.70M | -106.6% |
| 2020 | -$60.84M | -302.7% |
| 2019 | -$15.11M | -18.7% |
| 2019 | -$12.73M | -84.0% |
| 2018 | -$6.92M | +4.2% |
| 2017 | -$7.22M | +55.5% |
| 2016 | -$16.22M | +5.2% |
| 2015 | -$17.10M | -152.4% |
| 2013 | -$6.77M | -14948.2% |
| 2013 | -$45.0K | -273.5% |
| 2012 | -$12.1K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$10.33M | +55.1% | -1.0% |
| June 30, 2025 | -$10.22M | +45.7% | +43.9% |
| March 31, 2025 | -$18.22M | +20.7% | +20.8% |
| September 30, 2024 | -$23.01M | -1.4% | -22.3% |
| June 30, 2024 | -$18.82M | +27.7% | +18.1% |
| March 31, 2024 | -$22.99M | +18.3% | -1.3% |
| September 30, 2023 | -$22.69M | +41.4% | +12.8% |
| June 30, 2023 | -$26.03M | +42.8% | +7.6% |
- RELMADA THERAPEUTICS, INC. showed an increase of +29.6% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, RELMADA THERAPEUTICS, INC.’s operating income has declined by 490276.7% (from -$12.1 thousand to -$59.10 million).
- The most recent figure is from RELMADA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: